Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Pathology of benign prostatic hyperplasia

Abstract

The epidemiology of benign prostatic hyperplasia (BPH) is complex and not fully understood. The androgenic hormones testosterones and dihydrotestosterone play at least a permissive and important role. Growth factors and other hormones including estrogens may also play a role. BPH is a truely hyperplastic process resulting in growth of glandular-epithelial and stromal/muscle tissue in the prostate, leading to often measurable growth taking on different shapes and configurations which may impact symptoms and secondary outcomes. It is important to recognize that BPH is a histological conditions, which is one but not the only cause of lower urinary tract symptoms, and may or may not be associated with prostate enlargement and bladder outlet obstruction. Recognizing the different entities and determining their presence in individual patients may help with therapeutic decision making.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10

Similar content being viewed by others

References

  1. Roehrborn C, McConnell J . Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh P, Retik A, Vaughan E, Wein A (eds). Campbell's Urology, 8th edn. Saunders: Philadelphia, 2002, pp 1297–1336.

    Google Scholar 

  2. Cunha GR . Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. [Review]. Cancer 1994; 74: 1030–1044.

    Article  CAS  PubMed  Google Scholar 

  3. McConnell JD . Prostatic growth: new insights into hormonal regulation. [Review]. Br J Urol 1995; 76 (Suppl 1): 5–10.

    CAS  PubMed  Google Scholar 

  4. Wilson JD, Roehrborn C . Long-term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts. J Clin Endocrinol Metab 1999; 84: 4324–4331.

    Article  CAS  PubMed  Google Scholar 

  5. Peters CA, Walsh PC . The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia [published erratum appears in N Engl J Med 1988; 318(9): 580]. N Engl J Med 1987; 317: 599–604.

    Article  CAS  PubMed  Google Scholar 

  6. Marberger M, Roehrborn CG, Marks LS, Wilson T, Rittmaster RS . Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 91: 1323–1328.

    Article  CAS  PubMed  Google Scholar 

  7. Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004; 172 (4 Pt 1): 1399–1403.

    Article  CAS  PubMed  Google Scholar 

  8. Martikainen P, Kyprianou N, Isaacs JT . Effect of transforming growth factor-beta on proliferation and death of rat prostatic cells. Endocrinology 1990; 127: 2963–2968.

    Article  CAS  PubMed  Google Scholar 

  9. Kyprianou N, Isaacs JT . ‘Thymineless’ death in androgen-independent prostatic cancer cells. Biochem Biophys Res Commun 1989; 165: 73–81.

    Article  CAS  PubMed  Google Scholar 

  10. Barrack ER, Bujnovszky P, Walsh PC . Subcellular distribution of androgen receptors in human normal, benign hyperplastic, and malignant prostatic tissues: characterization of nuclear salt-resistant receptors. Cancer Res 1983; 43: 1107–1116.

    CAS  PubMed  Google Scholar 

  11. Rennie PS, Bruchovsky N, Goldenberg SL . Relationship of androgen receptors to the growth and regression of the prostate. Am JClin Oncol 1988; 11 (Suppl 2): S13–S17.

    Article  Google Scholar 

  12. Walsh PC, GM H, LL E . Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supernormal. J Clin Invest 1983; 72: 1772–1777.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Russell DW, Wilson JD . Steroid 5alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994; 63: 25.

    Article  CAS  PubMed  Google Scholar 

  14. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE . Steroid 5 alpha reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186: 1213.

    Article  CAS  PubMed  Google Scholar 

  15. Carson III C, Rittmaster R . The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003; 61 (4 Suppl 1): 2–7.

    Article  PubMed  Google Scholar 

  16. Lee KL, Peehl DM . Molecular and cellular pathogenesis of benign prostatic hyperplasia. J urol 2004; 172 (5 Pt 1): 1784–1791.

    Article  CAS  PubMed  Google Scholar 

  17. Griffiths K . Molecular control of prostate growth. In: Kirby R, McConnell J, Fitzpatrick JM, Roehrborn CG, Boyle P (eds). Textbook of Benign Prostatic Hyperplasia. Isis Medical Media: Oxford, 1996, pp 23–56.

    Google Scholar 

  18. Story MT, Livingston B, Baeten L, Swartz SJ, Jacobs SC, Begun FP et al. Cultured human prostate-derived fibroblasts produce a factor that stimulates their growth with properties indistinguishable from basic fibroblast growth factor. Prostate 1989; 15: 355–365.

    Article  CAS  PubMed  Google Scholar 

  19. Lawson RK . Role of growth factors in benign prostatic hyperplasia. Eur Urol 1997; 32 (Suppl 1): 22–27.

    CAS  PubMed  Google Scholar 

  20. McNeal JE . Origin and evolution of benign prostatic enlargement. Invest Urol 1978; 15: 340.

    CAS  PubMed  Google Scholar 

  21. McNeal J . Pathology of Benign Prostatic Hyperplasia. Insight into Etiology. In: Lepor H, Walsh PC (eds). The Urologic Clinics of North America, 17th edn. WB Saunders Company: Philadelphia, 1990, pp 477–486.

    Google Scholar 

  22. Caine MLS . The ‘capsule’ in benign prostatic hypertrophy. US Department of Health and Human Services 1987; No. 87-2881: 221.

    Google Scholar 

  23. Shapiro E, Becich MJ, Hartanto V, Lepor H . The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 1992; 147: 1293–1297.

    Article  CAS  PubMed  Google Scholar 

  24. Shapiro E, Hartanto V, Lepor H . Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color assisted image analysis. J Urol 1992; 147: 1167–1170.

    Article  CAS  PubMed  Google Scholar 

  25. Roehrborn CG, Schwinn DA . Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004; 171: 1029–1035.

    Article  CAS  PubMed  Google Scholar 

  26. Lepor H, Tang R, Shapiro E . The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate 1993; 22: 301–307.

    Article  CAS  PubMed  Google Scholar 

  27. Lepor H, Tang R, Meretyk S, Shapiro E . Alpha1 adrenoceptor subtypes in the human prostate. J Urol 1993; 149: 640–642.

    Article  CAS  PubMed  Google Scholar 

  28. Uckert S, Kuthe A, Stief CG, Jonas U . Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World J Urol 2001; 19: 14–22.

    Article  CAS  PubMed  Google Scholar 

  29. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401–1407.

    Article  CAS  PubMed  Google Scholar 

  30. McVary KT . Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005; 47: 838–845.

    Article  PubMed  Google Scholar 

  31. McVary KT, Razzaq A, Lee C, Venegas MF, Rademaker A, McKenna KE . Growth of the prostate gland is facilitated by the autonomic system. Biol Reprod 1994; 51: 99–107.

    Article  CAS  PubMed  Google Scholar 

  32. Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC . The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol 1979; 121: 640–642.

    Article  CAS  PubMed  Google Scholar 

  33. Azadzoi KM, Radisavljevic ZM, Siroky MB . Effects of ischemia on tachykinin-containing nerves and neurokinin receptors in the rabbit bladder. Urology 2008; 71: 979–983.

    Article  PubMed  Google Scholar 

  34. Azadzoi KM, Yalla SV, Siroky MB . Oxidative stress and neurodegeneration in the ischemic overactive bladder. J Urol 2007; 178: 710–715.

    Article  CAS  PubMed  Google Scholar 

  35. Oishi K, Boyle P, Barry M, Farah R, Gu F-L, Jacobsen S et al. Epidemiology and natural history of benign prostatic hyperplasia. In: 4th International Consultation on Benign Prostatic Hyperplasia. Plymbridge Distributors Ltd: Plymouth, United Kingdom, 1998, pp 23–59.

    Google Scholar 

  36. Girman CJ . Natural history and epidemiology of benign prostatic hyperplasia: relationship among urologic measures. Urology 1998; 51 (4A Suppl): 8–12.

    Article  CAS  PubMed  Google Scholar 

  37. Girman CJ, Epstein RS, Jacobsen SJ, Guess HA, Panser LA, Oesterling JE et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994; 44: 825–831.

    Article  CAS  PubMed  Google Scholar 

  38. Girman CJ, Jacobsen SJ, Guess HA, Oesterling JE, Chute CG, Panser LA et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 1995; 153: 1510–1515.

    Article  CAS  PubMed  Google Scholar 

  39. Girman CJ, Jacobsen SJ, Rhodes T, Guess HA, Roberts RO, Lieber MM . Association of health-related quality of life and benign prostatic enlargement. Eur Urol 1999; 35: 277–284.

    Article  CAS  PubMed  Google Scholar 

  40. McConnell J, Committee TMS . The long term effects of medical therapy on the progression of BPH: results from the MTOPS trial. J urol 2002; 167 (4 Suppl): 265A.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C G Roehrborn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roehrborn, C. Pathology of benign prostatic hyperplasia. Int J Impot Res 20 (Suppl 3), S11–S18 (2008). https://doi.org/10.1038/ijir.2008.55

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2008.55

This article is cited by

Search

Quick links